In its largest single-asset purchase ever, Takeda snaps up TYK2 drug for $4B upfront
Takeda is buying Nimbus’ late-stage TYK2 inhibitor, an oral drug for autoimmune diseases, for $4 billion in cash upfront. That sets Takeda up to compete with Bristol Myers Squibb, which got the first TYK2 inhibitor approval in September for psoriasis.
The Nimbus/Takeda deal is among the industry’s largest single-asset purchases dating back to 2008, after Amgen bought Otezla from Celgene in 2019 ($13.4 billion total), according to Chris Dokomajilar at DealForma. Nimbus can get another potential $2 billion if the drug, once on the market, reaches sales milestones — $1 billion for reaching annual net sales of $4 billion and another billion for net sales of $5 billion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.